Skip to main content
. Author manuscript; available in PMC: 2012 Oct 18.
Published in final edited form as: J Urol. 2010 Mar 20;183(5):1779–1785. doi: 10.1016/j.juro.2010.01.001

Figure 4.

Figure 4

Cumulative incidence of unfavorable biopsy (progression) (gray boxes) 3 years after initial surveillance biopsy in men without unfavorable biopsy at initial surveillance biopsy was based on initial surveillance biopsy results (negative vs positive for cancer if favorable pathological findings) and PSAD (less than 0.08 vs 0.08 ng/ml/cm3 or greater). n, total number of events at any time during followup in total number of patients at start of followup. Values in parentheses represent 95% CI.